Logo Image
|Videos|June 25, 2021

The Benefit of COVID-19 & Flu Vaccine Co-Administration

Plus: how could the COVID-19 testing market boom improve public flu awareness?

Though Novavax and Seqirus are the first collaborative COVID-19 vaccine and influenza vaccine developers, respectively, to present positive findings of co-administration in volunteers, there is anticipation this may become a standard practice in the coming fall and winter seasons.

What exactly COVID-19 and flu vaccine co-administration may look like is not yet well-defined, but experts anticipate it could be a win-win practice.

In the next segment of an interview with Contagion, Dr. Raja Rajaram, Medical Affairs Lead of EMEA at Seqirus, discussed how the trend of flu vaccination as a “behavioral norm” may help improve global COVID-19 immunization efforts.

“Some of the population may be going forward for their flu vaccines, and that is an opportunity to find out if they’ve had their COVID-19 vaccines,” he explained. At the same time, COVID-19 vaccine appointments may be an ideal opportunity to initiate flu vaccination behaviors in patients as well.

Rajaram also discussed the rapidly-expanding respiratory virus assay market, and how the switch from defining flu by test results rather than diagnostic code may help public health awareness efforts.

“What I do hope for after COVID-19 is that (the testing market) expands to include flu and other respiratory viruses, because it will help the public understand what is the disease burden every winter,” he said.

Related to this article

View more
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
Read more
GSK's mRNA Influenza Vaccine Moves to Phase 3 Trial
GSK's mRNA Influenza Vaccine Moves to Phase 3 Trial
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.
Read more
How The Food Safety Surveillance Infrastructure Works in the US
How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Read more
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Read more